Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Adult patients with ESBL-producing Gram negative infections are randomized to receive
ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups
are compared.